Surgical resection remains the hallmark therapy for primary colon cancer. It allows the patients to become clinically disease free, provides proper staging, and determines who should receive adjuvant systemic chemotherapy. Treatment options for patients with unresectable metastatic disease have improved significantly in the past few years. A review of the published data in the treatment of patients with stage IV colorectal cancer, outlining the surgical and medical therapeutic options demonstrates that medical management, with combinations of cytotoxic chemotherapy, and/or biological agents, has resulted in an unprecedented median survival>20 months. However, these therapeutic combinations are not an optimal therapeutic strategy for all categories of stage IV disease. Systemic treatment alone is no longer appropriate for patients with limited peritoneal dissemination from a primary or recurrent colon cancer. The surgical management of peritoneal surface malignancies of colonic origin with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) has been clearly defined and continues to improve. Better surgical techniques that include peritonectomy procedures, standardized methods to deliver intraoperative hyperthermic intraperitoneal chemotherapy and better patient selection criteria, have resulted in a significant improvement in survival and in morbidity and mortality of the surgical management of this particular group of stage IV colon cancer patients.
MATERIALS AND METHODS
Upon review of the literature, we have identified a subset of patients with metastatic disease confined to the abdomen and with no evidence of hematogenous spread, referred to as peritoneal carcinomatosis without distant disease. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with mitomycin C and post-operative systemic chemotherapy, has resulted in a median survival of up to 42 months in these patients when a complete cytoreduction is achieved. On 14-16 January 2006 the first International Symposium on Regional Cancer Therapies was held in Snowmass, Colorado. Surgical options in the management of peritoneal surface malignancies of colonic origin (Table 1) , were reviewed and discussed by some representatives from the major Peritoneal Surface Malignancy Centers from around the world. During a follow up meeting on 24 March 2006 in San Diego, CA, while attending the Society of Surgical Oncology annual meeting, further discussions concluded in agreement on a registry database sheet and using the Peritoneal Cancer Index as a scoring system ( Table 2) . Based on the analysis of published data, we present a Consensus Statement on the treatment of patients with recurrent and/or metastatic colon cancer with peritoneal involvement (Fig. 1 ).
Rigorous Diagnostic Work-up
Proper patient selection has been shown to be a crucially important aspect of this treatment plan. Once a patient has been diagnosed with colon cancer with peritoneal involvement, the work-up should include a complete colonoscopic evaluation as well as a CT scan of the chest, abdomen and pelvis with maximum oral and IV contrast to evaluate the extent of peritoneal dissemination. A PET scan can be considered if there is any question of extra-abdominal disease.
Best Systemic Therapy
Patients that are diagnosed as having peritoneal carcinomatosis and other sites of dissemination and that have a good performance status, should receive the best combination of cytotoxic chemotherapy and biological agents. If they have a good response to the systemic therapy and/or if they have limited liver involvement, they may be considered for cytoreductive surgery and intraperitoneal chemotherapy at a later time. There is currently little data to guide us as to whether such chemotherapy is best given before or after cytoreductive surgery and HIPEC. However, we feel that patients should be evaluated by surgical oncologists experienced in these techniques prior to embarking on systemic therapy alone for patients who may be candidates for HIPEC.
Variables Associated with Increased Chances of having a Complete Cytoreduction
Complete cytoreduction means that no macroscopic residual disease was left after the operative procedure. The following are clinical and radiographic variables that are usually associated with increase chances of achieving a complete removal of all tumor greater than 2.5 mm:
(1) ECOG performance status two or less; (2) no evidence of extra-abdominal disease; (3) up to three small, resectable parenchymal hepatic metastases; (4) no evidence of biliary obstruction; (5) no evidence of ureteral obstruction; (6) no evidence of intestinal obstruction at more than one site; (7) small bowel involvement: no evidence of gross disease in the mesentery with several segmental sites of partial obstruction; (8) small volume disease in the gastro-hepatic ligament. Cytoreductive surgery will include peritonectomy procedures in order to remove all visible tumor. If a complete cytoreduction, CC-0/CC-1 by the completion of cytoreduction score or a R0/R1 by the R scoring system is achieved (see Table 2 ), then the patients will undergo hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C (15-35 mg/m 2 ) with a target intraperitoneal temperature of 39-42°C for 60-120 min. Whether an open or closed method for the chemotherapeutic perfusion is used, and whether or not early post-operative intraperitoneal chemotherapy (EPIC) with 5 days of 5-FU is used, will be the surgeonÕs preference. In those patients with symptomatic ascites in whom an adequate cytoreduction could not be achieved, HI-PEC could be performed at the discretion of the surgeon with the intention of palliating the intractable ascites. Although mitomycin C is the most commonly used drug, we recognized that oxaliplatin is being used more frequently with very promising results.
Complete Cytoreduction Not Possible
In those patients with clear evidence of incomplete cytoreduction, surgery should be performed to relieve symptoms at the discretion of the operating surgeon. 
